NCT02113319

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Français Des leucémie aiguë myéloblastique

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: University Hospital, Angers · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal Residual Disease after chemotherapy is predictive of relapse. The relapse risk is also increased in case of mutations of receptors tyrosine kinase. For patients with a high Minimal Residual Disease level at the end of consolidation or in molecular relapse, maintenance by the inhibitor dasatinib is proposed.

Conditions

• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
DRUG	dasatinib	dasatinib 50 mg and 20 mg During one year

Timeline

• Start date: 2007-04-01
• Primary completion: 2012-05-01
• First posted: 2014-04-14
• Last updated: 2014-04-14

Locations

1 site across 1 country: France